(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 178.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.91%.
Taysha Gene Therapies's revenue in 2026 is $6,310,000.On average, 14 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,201,958,209, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $4,314,230,125. On average, 8 Wall Street analysts forecast TSHA's revenue for 2027 to be $6,888,524,392, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $26,529,091,275.
In 2028, TSHA is forecast to generate $43,328,566,421 in revenue, with the lowest revenue forecast at $25,072,388,049 and the highest revenue forecast at $81,690,974,610.